Lawrence Fisher, MD
Cardiology · Danbury, CTNPI 1265427751
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Edwards Lifesciences at 56.1% of the total.
Across 4 payments — averaging $41.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$92
- Abbott$28
- Medtronic$25
- E.r. Squibb & Sons, L.L.C.$19
What the payments were for
- Food & beverage$165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 1 | $92 |
| Abbott | 1 | $28 |
| Medtronic | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
How this compares
$165 in reported general payments places this provider in the 80th percentile of 28 cardiology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 600 | $730,760 |
| XareltoRivaroxaban | 141 | $202,948 |
| EntrestoSacubitril/Valsartan | 92 | $140,088 |
| FarxigaDapagliflozin Propanediol | 33 | $43,369 |
| Repatha SureclickEvolocumab | 54 | $42,005 |
| JardianceEmpagliflozin | 24 | $31,945 |
| Praluent PenAlirocumab | 26 | $16,722 |
| Metoprolol Succinate | 620 | $10,245 |
| Atorvastatin Calcium | 595 | $5,377 |
| Rosuvastatin Calcium | 313 | $5,042 |
| Valsartan | 164 | $4,411 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $4,300 |
| Metoprolol Tartrate | 486 | $3,913 |
| Ranolazine ErRanolazine | 27 | $3,700 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 118 | $3,668 |
Paid to pharmacies, not to this prescriber.
Other cardiology in Danbury
- Alexandra LanskyNew Haven$195K
- Shashank JainNew Haven$14K
- Neiberg de Alcantara LimaWillimantic$8K
- Leonid KarpenosWestport$1K
- Robert SmithHartford$823
- Aline IskandarManchester$0
- Elise MeoliNew Haven$0
- Valerie PopkinWaterford$0
- Arya ManiNew Haven$0
- Arthur SeltzerNorth Haven$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.